Group 1 - The core point of the announcement is the transfer of shares by Guotou High-Tech Investment Co., Ltd. and its concerted action partner Hangzhou Chuanghe Selected Venture Capital Partnership, which reduced their holdings in Xiduan Pharmaceutical to below 5% [3][9][48] - The share transfer involved 765,000 shares at a price of 24.69 yuan per share, totaling 18,887,850 yuan [3][24][26] - After the transfer, the combined shareholding of Guotou High-Tech and Hangzhou Chuanghe decreased to 4.13% of the total share capital of Xiduan Pharmaceutical [3][48] Group 2 - The transfer was conducted through a non-public inquiry transfer method and did not involve a public offering or trigger a mandatory bid [3][10] - The transfer process was organized by Huatai United Securities, which ensured compliance with relevant regulations and fairness in the inquiry process [14][33] - The inquiry transfer was completed on July 3, 2025, and the relevant disclosures were made in accordance with regulatory requirements [4][27][28] Group 3 - The transfer does not affect the control of the company, as the transferring parties are not the controlling shareholders or actual controllers of Xiduan Pharmaceutical [9][48] - The inquiry transfer was open to specific institutional investors, with five institutions ultimately participating in the share acquisition [11][25] - The inquiry transfer price was determined based on the average trading price of the company's shares over the previous 20 trading days, ensuring it met regulatory guidelines [12][19]
吉林省西点药业科技发展股份有限公司股东询价转让结果报告书暨持股5%以上股东持有权益比例降至5%以下的权益变动提示性公告